Biogen Idec (NQ: BIIB )
257.01 -0.82 (-0.32%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
All News about Biogen Idec
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Topics Artificial Intelligence
Exposures Artificial Intelligence
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
August 17, 2023
From Brodsky & Smith LLC